Evidence map›Paper›PMID 42828019›Full record

ArticlePeerJ2026

Exploratory effects of coffee-derived exosome-like nanoparticles in a fibrillar amyloid-beta 1-42-induced neurodegenerative rat model: evidence from fluorodeoxyglucose positron emission tomography and phosphorylated tau/amyloid precursor protein expression.

Yusuf Kucukbagriacik, Gulistan Sanem Saribas, Kahraman Ates, Cenan Ozturk, Eren Kahyaoglu, Sezen Kislal, C Ceren Akgul, A Ozgur Karacalioglu, Cuneyt Goksoy, Murat Kantarcioglu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yusuf KucukbagriacikDepartment of Biophysics, Gulhane Medical Faculty, University of Health Sciences, Ankara, Turkey.ORCID 0000-0002-4909-2669
Gulistan Sanem SaribasDepartment of Histology and Embryology, Gulhane Medical Faculty, University of Health Sciences, Ankara, Turkey.
Kahraman AtesDepartment of Biophysics, Gulhane Medical Faculty, University of Health Sciences, Ankara, Turkey.
Cenan OzturkDepartment of Biology, Faculty of Science, Ankara University, Ankara, Turkey.
Eren KahyaogluDepartment of Molecular Biology and Genetics, Faculty of Arts and Sciences, Nevsehir Hacı Bektaş Veli University, Nevsehir, Turkey.
Sezen KislalDepartment of Psychology, Faculty of Arts and Science, Middle East Technical University, Ankara, Turkey.
C Ceren AkgulDepartment of Psychology, Faculty of Arts and Science, Middle East Technical University, Ankara, Turkey.ORCID 0009-0005-0262-2246
A Ozgur KaracaliogluDepartment of Nuclear Medicine, Gulhane Medical Faculty, University of Health Sciences, Ankara, Turkey.
Cuneyt GoksoyDepartment of Biophysics, Gulhane Medical Faculty, University of Health Sciences, Ankara, Turkey.
Murat KantarciogluDepartment of Gastroenterology, Faculty of Medicine, Yuksek Ihtisas University, Ankara, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta 1-42 (Aβ Methods: Fifty male Results: MicroPET imaging demonstrated a significant, dose-dependent increase in cerebral glucose metabolism in AD rats treated with CELNs compared with the untreated AD group. Histopathological evaluations were consistent with the imaging data: in AD groups receiving CELNs, phospho-tau and beta-amyloid precursor protein expression were significantly reduced in the hippocampal cornu ammonis 2 (CA2) and dentate gyrus regions compared with the untreated AD group. Conclusions: In this exploratory fibrillar Aβ

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorCoffeeExosomesNanoparticlestau ProteinsAnimalsDisease Models, AnimalFluorodeoxyglucose F18MalePeptide FragmentsPhosphorylationPositron-Emission TomographyRatsRats, Sprague-DawleyAmyloid beta-Peptidesamyloid beta-protein (1-42)Amyloid beta-Protein PrecursorCoffeeFluorodeoxyglucose F18Peptide Fragmentstau ProteinsAlzheimer’s diseaseAmyloid-betaCELNsCoffee-derived exosome-like nanoparticlesFDG-PET

Identifiers

PMID42828019
PMCPMC13632683

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.